Added to YB: 2026-10-09
Pitch date: 2026-10-04
NUVB [bullish]
Nuvation Bio Inc.
-7.23%
current return
Author Info
No bio for this author
Company Info
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.
Market Cap
$1.7B
Pitch Price
$5.12
Price Target
N/A
Dividend
N/A
EV/EBITDA
-11.01
P/E
-11.12
EV/Sales
8.65
Sector
Pharmaceuticals
Category
special_situation
M&A Hunter Portfolio Update: Tier 3 Core Convictions (Under $10) - Nuvation Bio Inc.
NUVB (hold): Nuvation Bio is now a commercial and pipeline oncology company after Ibtrozi won FDA approval for ROS1-positive non-small-cell lung cancer, with updated duration-of-response information later approved in TKI-naïve disease. A solid-tumor buyer could value the ROS1 franchise and broader portfolio, but urgency is limited because individual assets could be partnered or acquired separately and the franchise still must prove durable demand and differentiation.
Read full article (1 min)